1. Introduction {#s0005}
===============

Major depressive disorder (MDD) is a leading cause of disability and an important contributing factor to the worldwide burden of disease; it can directly cause mortality due to suicide and indirectly through affecting prognosis of chronic conditions such as ischemic heart disease ([@b0440]). The inflammation hypothesis of depression proposes that MDD is also associated with sustained activation of the innate immune system leading to increased production of proinflammatory cytokines and acute phase proteins ([@b0260; @b0365]). In support of this hypothesis, several studies have detected higher levels of inflammation in depressed individuals than in healthy controls, although the strength of evidence varies depending on which specific inflammatory markers have been examined, i.e. interleukin (IL)-6, IL-1β, tumour necrosis factor (TNF)-α and C-reactive protein (CRP) ([@b0075; @b0165; @b0175; @b0255; @b0410]).

In a cumulative meta-analysis, the results from individual studies are added chronologically and the aggregate effect estimate recomputed after addition of each study. The purpose of this technique is to determine the point at which further studies carried out in a similar manner are unlikely to change the conclusion. Importantly, information in these analyses may help researchers to justify additional studies or to become aware of the need for redirecting their research efforts ([@b0035]). Here, we have applied this approach to evaluate the strength of the association between specific inflammatory markers (IL-6, IL-1β, CRP-α, TNF) and MDD.

2. Materials and methods {#s0010}
========================

2.1. Literature search and data extraction {#s0015}
------------------------------------------

We performed a systematic search of the literature using PubMed, Embase, PsychInfo to include publications until May 2014 with the following search terms: \["*depression*"\], \["*depressive*"\], \["*C-reactive protein*"\], \["*CRP*"\], \["*interleukin 6*"\], \["*IL-6*"\], \["*tumour necrosis factor α*"\], \[*TNF-alpha*"\], \["*interleukin 1β*"\], \[*IL-1beta*"\], \["*cytokine*"\]. We also scrutinised the reference lists of all of the relevant publications identified. In addition, we used the Institute of Scientific Information Web of Science (May 2014) to retrieve all the studies citing the studies identified by the search. Information from the articles included in the meta-analysis reporting an association between CRP ([@b0175]), IL-6, TNF-α, IL-1β ([@b0075; @b0165; @b0175; @b0255]) and depression in cross-sectional settings was reviewed and retracted. Data were searched and extracted independently by two authors (RH and JM), the results were compared and consensus obtained through discussion. [Supplementary Fig. 1](#s0120){ref-type="sec"} shows the literature search strategy.

2.2. Selection criteria {#s0020}
-----------------------

The immune markers evaluated in this study were selected based on their effects on the development of sickness behaviour (IL-1β and TNF-α) ([@b0045; @b0050]) and previous meta-analyses suggesting possible associations of peripheral levels of IL-1, ([@b0175]) TNF-α, ([@b0075; @b0255]) and IL-6, ([@b0075; @b0165; @b0255]) CRP ([@b0175]) with depression. Previous meta-analyses did not support the involvement of IL-10, ([@b0075; @b0165; @b0255]) IL-4, ([@b0075; @b0255]) IL-8, ([@b0075; @b0255]) IL-2, ([@b0075; @b0255]) or IFN-γ ([@b0075; @b0255]) in depression, and therefore these cytokines were not included in this analysis.

Specific inclusion criteria were (1) measurement of unstimulated cytokines from the blood; (2) comparison of adult patients with MDD and psychiatrically healthy controls; (3) use of structured clinical assessments (SCID or MINI) based on DSM-III/DSM-IV criteria to verify unipolar MDD; (4) incorporation of study subjects without major physical illness (i.e. diabetes, heart disease, cancer etc.) at the time of assessment. Studies focusing on pregnant women, postpartum depression or including patients with metabolic syndrome were excluded from the meta-analysis, whereas studies targeting patients with stable medical conditions, such as hypertension were included. Studies where participants used any medications at the time of blood sampling were referred to as "*subjects using medication*". Individuals that had undergone a washout period from antidepressants before entering the study or at the time of immune assessments were referred to as "*subjects not using antidepressant medication*". The median washout period in the included studies was 4 weeks with a range between 1 week and 3 months ([Supplementary Table 3](#s0120){ref-type="sec"}).

2.3. Quality assessment {#s0025}
-----------------------

This meta-analysis was conducted according to PRISMA guidelines ([@b0295]). For evaluation of the quality of included studies, we used the Newcastle-Ottawa quality assessment scale (NOS) for case-control studies ([@b0435]) In this method, each study can obtain a maximum of 9 points in three categories; selection of study participants (adequate definition, validation and representativeness of cases and controls), comparability of cases and controls, and the ascertainment of exposure ([Supplementary Table 1](#s0120){ref-type="sec"}). In line with the recommendations of the Meta-Analysis of Observational Studies, ([@b0370]), we performed a sensitivity analysis excluding those studies with poor quality (NOS score \< 6). We also performed an additional quality analysis using the score of 7 as the cut-off value.

2.4. Data synthesis {#s0030}
-------------------

The statistical package Comprehensive Meta-analysis (version 2) was used for data analysis. Effect sizes were calculated using standardised mean differences (Cohen's *d*) from mean (±SD) concentrations of each immune marker measured in the blood of MDD patients and non-depressed controls. If concentrations of immune markers were not reported, we extracted the effect size from exact *p*-values and sample size ([@b0040; @b0095; @b0170; @b0250]). When relevant data were not reported, ([@b0125; @b0275; @b0430; @b0455]) we first contacted the authors for assistance and if not successful, retrieved values from graphs using DataThief III, version 1.6. ([@b0400]).

A cumulative meta-analysis was performed by sorting of the included studies according to the date of publication. The *p*-values represent the summary statistics of all incorporated studies (rather than *p*-values for independent studies), enabling the inspection of the contribution of each new study to the overall effect estimate. Due to the variation in effect sizes across studies and to achieve generalisation of the results, a random-effects model was used in the analysis of total data and in the meta-regression. Random-effects models take into account both within- and between-study variability, and provide a more conservative estimate of effect sizes than can be obtained with the fixed-effect models. Heterogeneity across studies was assessed using Cochrane's *Q* and *p* \< 0.10 was considered as significant. The *I*^2^ index \< 25% was defined as 'low', 50% as 'moderate' and 75% 'high' heterogeneity ([@b0155]). Publication bias was examined using Egger's regression intercept and Begg and Mazumdar's rank correlation. We used four criteria to determine whether further research conducted in the same manner is likely to be needed to confirm the conclusion: (1) the association has reached statistical significance several years ago and the effect size has remained unchanged after the addition of more recent studies; (2) in the total evidence, there is very little heterogeneity in study-specific estimates; (3) any subgroup differences are small; and (4) publication bias is an unlikely explanation for the findings.

Potential covariates were selected, based on earlier reports showing associations of age, gender and BMI with both inflammatory markers and depression ([@b0165; @b0175; @b0255]). When data were presented separately for different subgroups of patients, we computed a combined effect size for final analysis. Mean age of study population (\>40 vs. ⩽40 years), gender (\>50% vs. ⩽50% of study subjects female), sample size (over 50 subjects was defined as large), sample quality (⩾6 was defined as high quality), patient type (inpatient vs. outpatient) and BMI (controlled for vs. not controlled) were used as categorical effect modifiers in the subgroup analyses. In the sensitivity analysis, we performed meta-analyses using only high quality studies according to two different cut-off scores (NOS ⩾ 6 and ⩾ 7) and studies including only participants not using antidepressants at the time of blood sampling.

3. Results {#s0035}
==========

After excluding duplicates, reviews, animal studies and non-relevant studies, the full texts of remaining articles (*n* = 209) were inspected in detail ([Supplementary Fig. 1](#s0120){ref-type="sec"}). Articles were excluded when a diagnosis of MDD was not made according to Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria and when studies did not employ sufficiently exact and specific patient exclusion criteria (*N* = 93). We excluded studies which had included patients with minor depression (*N* = 1) and bipolar disorder (*N* = 2) in addition to MDD patients. Studies were also excluded if patients suffered from a significant comorbid disease (*N* = 31), or if the study lacked a proper control group (*N* = 16), if inflammatory marker measurements had been assayed in fluids other than venous blood (*N* = 5) or if *in vitro* stimulated cytokines had been used to assess immune function (*N* = 3). In total, 58 articles met the inclusion criteria: 20 studies for CRP ([@b0030; @b0070; @b0115; @b0130; @b0170; @b0185; @b0195; @b0210; @b0215; @b0230; @b0240; @b0315; @b0330; @b0335; @b0340; @b0360; @b0390; @b0395; @b0430; @b0465]), 31 studies for IL-6 ([@b0005; @b0015; @b0040; @b0055; @b0080; @b0095; @b0100; @b0105; @b0115; @b0140; @b0185; @b0205; @b0210; @b0215; @b0245; @b0265; @b0270; @b0275; @b0290; @b0300; @b0310; @b0315; @b0320; @b0325; @b0340; @b0355; @b0360; @b0425; @b0430; @b0455; @b0460]), 31 studies for TNF-α ([@b0040; @b0065; @b0070; @b0080; @b0085; @b0090; @b0095; @b0100; @b0110; @b0125; @b0170; @b0180; @b0185; @b0205; @b0210; @b0245; @b0250; @b0280; @b0285; @b0290; @b0305; @b0310; @b0315; @b0320; @b0330; @b0350; @b0355; @b0385; @b0395; @b0430; @b0455]) and 14 studies for IL-1β ([@b0040; @b0060; @b0110; @b0145; @b0150; @b0180; @b0185; @b0205; @b0245; @b0320; @b0330; @b0355; @b0390; @b0455]). [Supplementary Table 2](#s0120){ref-type="sec"} presents the descriptive and quality data of each study and [Supplementary Table 3](#s0120){ref-type="sec"} shows the specific inclusion and exclusion criteria used in these studies.

3.1. Cumulative meta-analyses {#s0040}
-----------------------------

### 3.1.1. Interleukin 6 {#s0045}

The cumulative meta-analysis showed a medium-sized association between IL-6 and MDD (*N* = 31, combined *d* = 0.54, 95% CI = 0.40--0.69, total *N*(MDD) = 1045, total *N*(non-MDD) = 977) ([Fig. 1](#f0005){ref-type="fig"}). A statistically significant association (*p* \< 0.0001) was first achieved in 2006, and this result has remained unchanged after 23 more studies published between the years 2006 and 2014. Moderate heterogeneity between studies was detected (*Q* = 68.5, *p* \< 0.0001, *I*^2^ = 56.2%), but there was no apparent publication bias: Begg and Mazumdar's tau 0.16 (*p* = 0.21), Egger's regression intercept 1.13 (*p* = 0.30).

### 3.1.2. C-reactive protein {#s0050}

There was a medium-sized association between CRP and MDD (*N* = 20, combined *d* = 0.47; 95% CI = 0.28--0.65, total *N*(MDD) = 746, total *N*(non-MDD) = 679) ([Fig. 2](#f0010){ref-type="fig"}). Statistical significance (*p* \< 0.0001) was achieved after 14 studies, and the association did not change after supplementing with six more studies. Heterogeneity between studies was moderate (*Q* = 51, *p* \< 0.0001, *I*^2^ = 62%) and no apparent publication bias was notified (Begg and Mazumdar's tau 0.06 (*p* = 0.72), Egger's regression intercept 1.02 (*p* = 0.47).

### 3.1.3. Tumour necrosis factor α {#s0055}

The pooled evidence showed increased blood levels of TNF-α in MDD patients (*N* = 31, combined *d* = 0.40, 95% CI = 0.15--0.65, total *N*(MDD) = 1214, total *N*(non-MDD) = 1262) ([Fig. 3](#f0015){ref-type="fig"}). The effect reached statistical significance (*p* \< 0.05) after 14 studies in 2009 and the size of the association did not substantially change after the publication of 17 additional articles. Heterogeneity in study-specific effect estimates was high (*Q* = 254, *p* \< 0.0001, *I*^2^ = 88%), suggesting that systematic differences existed between studies. There was no apparent publication bias (Begg and Mazumdar's tau 0.22 (*p* = 0.08), Egger's regression intercept 2.91 (*p* = 0.12).

### 3.1.4. Interleukin 1β {#s0060}

IL-1β was not associated with MDD (*N* = 14, combined *d* for all studies = −0.05, 95%CI = −0.57--0.48, total *N*(MDD) = 491, total *N*(non-MDD) = 509) ([Fig. 4](#f0020){ref-type="fig"}). There was extensive heterogeneity between studies (*Q* = 197, *p* \< 0.0001, *I*^2^ = 93%), but no publication bias (Begg and Mazumdar's tau −0.09 (*p* = 0.66), Egger's regression intercept was −0.25 (*p* = 0.96).

3.2. Additional analyses {#s0065}
------------------------

### 3.2.1. Sensitivity analyses {#s0070}

When only high quality studies (NOS-score ⩾ 6) were included in the analysis, the association between IL-6 and MDD remained statistically significant and stable after completion of the first five studies (*N* = 21 studies, *d* = 0.60, 95%CI = 0.42--0.78, total *N*(MDD) = 781, total *N*(non-MDD) = 711, *p* \< 0.0001) ([Table 1](#t0005){ref-type="table"}). Including only subjects not using antidepressants decreased the total number of studies to 16, but the association remained strong and statistically significant after the publication of 11 recent studies (*d* = 0.65, *p* \< 0.0001) ([Supplementary Fig. 2A](#s0120){ref-type="sec"}). Using the alternative cut-off score ⩾7 for high quality revealed that the association had remained significant and unaltered since the publication of the first four studies (*N* = 8, *d* = 0.65, *p* \< 0.0001).

With respect to CRP, exclusion of lower quality studies (NOS-score \< 6) confirmed the positive association with MDD: *N* = 10, *d* = 0.69, 95%CI = 0.43--0.95, total *N*(MDD) = 395, total *N*(non-MDD) = 321) ([Table 1](#t0005){ref-type="table"}). Further exclusions of the studies allowing the use of medications during the blood draw sampling led to even increased effect size estimates (*d* = 0.88, *p* \< 0.0001). These associations have remained unaltered since 1996 to 2014 after completion of seven additional studies ([Supplementary Fig. 2B](#s0120){ref-type="sec"}). The use of the cut-off score ⩾7 for quality assessment left only five studies for analysis; however, the association still remained statistically significant (*d* = 0.69, *p* = 0.002).

In the analysis of high quality studies, the association between TNF-α and MDD weakened and changed to being statistically non-significant (*N* = 18, *d* = 0.28, *p* = 0.09, 95%CI = −0.04--0.59 total *N*(MDD) = 805, total *N*(non-MDD) = 872) ([Table 1](#t0005){ref-type="table"}). Further exclusion of studies permitting the concomitant use of medications resulted in a positive but statistically unstable association between TNF-α and MDD (*N* = 12, *d* = 0.57, *p* = 0.004) ([Supplementary Fig. 2C](#s0120){ref-type="sec"}).

Our sensitivity analysis confirmed the lack of association between IL-1β and MDD in the high quality (NOS [\>]{.ul} 6) studies restricted to patients free of antidepressant medication (*N* = 9, *d* = −0.36, *p* = 0.29) ([Supplementary Fig. 2D](#s0120){ref-type="sec"}).

### 3.2.2. Subgroup differences {#s0075}

Age, gender, BMI, medication use, study size or patient type did not modify the association between IL-6 and MDD ([Table 1](#t0005){ref-type="table"}). TNF-α was significantly related to MDD in studies restricted to antidepressant-free subjects (*p* = 0.001), studies including younger participants (age \< 40) (*p* = 0.001), as well as those not controlling for BMI (*p* = 0.006) and including more female than male study subjects (*p* = 0.004). The association between IL-1β and MDD was statistically significant only in older patients (*p* \< 0.0001).

Majority of studies (*N* = 38, 66%) reported depressive symptoms being severe or very severe ([Supplementary Table 4](#s0120){ref-type="sec"}). Severe depression was more strongly associated with IL-6, CRP and TNF-α compared to moderate depression ([Table 1](#t0005){ref-type="table"}).

A meta-regression revealed that a higher mean age was associated with weaker associations between TNF-α and MDD (*p* = 0.01), and stronger associations between IL-1β and MDD (*p* = 0.007). There was a suggestive trend towards stronger associations between IL-6 and MDD with increased mean age (*p* = 0.06). No significant associations between immune markers and HAMD score (an indicator of the severity of symptoms) were found.

### 3.2.3. Other Axis I/II disorders and depression subtypes {#s0080}

Information on other Axis I or Axis II diagnoses, such as generalised anxiety disorders or any anxiety or psychotic disorders, panic disorder, phobia, obsessive--compulsive disorder, post-traumatic stress disorder, schizophrenia or bipolar disorder, had been included in 27 (47%) of the 58 studies ([Supplementary Table 4](#s0120){ref-type="sec"}). Fifteen (26%) studies did not assess or report other Axis I or Axis II disorders and 26% excluded all patients with any other Axis I or Axis II disorder other than MDD. Thirteen studies (22%) excluded patients with psychotic features, 10 (17%) with bipolar disorder and 4 (7%) with comorbid anxiety symptoms.

Most studies (72%) did not include information on the different subtypes of MDD. MDD with melancholic features had been investigated in 10 (17%) studies, atypical and suicidal/non-suicidal MDD in 3 (5%) and treatment-resistant MDD in 5 (9%) studies. Given the large variability in study-specific inclusion and exclusion criteria for other Axis I/II disorders and a small number of studies specifying different depression subtypes, we could not assess the role of these covariates on the depression-inflammation relation.

### 3.2.4. Pharmacotherapy {#s0085}

From the 39 studies not allowing antidepressant medication during the inflammatory marker assessments, 35 (90%) specified the use of SSRIs and/or other classes of antidepressants as an exclusion criterion and four studies (10%) used the term "medication free" as their inclusion criterion ([Supplementary Table 4](#s0120){ref-type="sec"}). Fourteen studies (36%) had specified the concomitant use of antidepressants and other psychotropic medications (including anxiolytics, antipsychotics and/or mood stabilizers) as exclusion criteria and 14 (36%) excluded patients using both antidepressant and anti-inflammatory medications.

### 3.2.5. Lifestyle factors {#s0090}

Twenty-two (38%) studies included smokers, 16 (28%) studies did not give information on substance use (smoking, drinking or drug use) and 24 (41%) had excluded patients with drug abuse or substance dependence ([Supplementary Table 4](#s0120){ref-type="sec"}). Since only 6 (10%) of studies had excluded subjects who were smokers, the role of smoking on inflammation--depression associations could not be verified. In the high-quality studies with subjects not using antidepressants, 12/16 (75%) for IL-6 and 5 of 7 studies (71%) for CRP had excluded patients with previous/current substance abuse.

### 3.2.6. Other potential covariates {#s0095}

Other covariates available in some of the studies, such as the number of depression episodes and the duration and age of onset of depressive disorder ([Supplementary Table 3](#s0120){ref-type="sec"}), were not considered in the current meta-analysis. The effect of physical comorbidity on the inflammatory marker--depression association could not be tested given the nature of the available information.

4. Discussion {#s0100}
=============

Using cumulative meta-analysis, we sought to determine the strength of the totality of evidence and the year when the association between specific immune markers and major depressive disorder first reached statistical significance. In addition, we explored the effect of subsequent studies on the overall effect size enabling us to evaluate whether new studies are likely to change these associations ([@b0035]). We found strong support for higher circulating IL-6 concentrations in patients with major depression in comparison to non-depressive individuals. This association has remained essentially unchanged from 2006 until the present date and including 23 additional studies. Similarly, the CRP--major depression relationship is robust and has been unaltered since 2012 after addition of six more recent publications. Nonetheless, these additional data, while having only a marginal effect on the overall effect size estimate, have narrowed the 95% confidence intervals. Additional sensitivity analyses incorporating only high-quality studies of subjects not receiving antidepressant drug treatment further strengthened these relationships, evidence that the observed associations are robust and unlikely to change should new studies be conducted using similar designs.

Our findings on IL-6 and CRP are in agreement with preclinical data showing a plausible role of IL-6 in the pathology of depressive-like behaviour ([@b0025; @b0380]), predictive associations of IL-6 and CRP with the future development of mood disorders ([@b0120; @b0220; @b0225; @b0420; @b0445]), evidence of dose--response relationships ([@b0225]) and associations of these inflammatory markers with therapeutic response to antidepressants and ketamine ([@b0020; @b0040; @b0160; @b0450]). Our findings also confirm those reported in previous meta-analyses which included a smaller number of cross-sectional ([@b0075; @b0255]) and longitudinal studies ([@b0410]) on IL-6 and CRP. Subgroup analysis showed that the associations of IL-6 and CRP concentrations with major depression remained relatively stable when assessing the effect of age, gender, BMI, study size or study quality on overall effect estimate.

The association between TNF-α and major depression, although the volume of existing research for this inflammation marker is equal to or even greater than that examining IL-6 or CRP, was less convincing: the overall effect size was smaller, the findings in sensitivity and subgroup analyses were less consistent and, importantly, the association was attenuated in higher quality studies and studies controlling for obesity. These results may result from a weaker association, failure to properly control for confounding factors ([@b0165]) or difficulties in measuring accurately this inflammatory marker. In all these cases, improvements in research protocols and study designs, rather than simply more research conducted in a similar manner, are needed. Furthermore, the divergent effects of anti-TNF-α therapy on depressive symptoms ([@b0235]) point to the existence of potential confounders moderating the strength of the association between TNF-α and major depression.

Aggregate data from the 15 studies on IL-1β did not convincingly confirm or refute an association with major depression. The summary effect estimate based on these 15 studies was completely null, whereas for CPR and IL-6, the summary estimate had reached statistical significance after the completion of 14 or 8 studies, respectively. Elevated IL-1β levels in subjects with major depression, in comparison to non-depressive controls, were observed only in studies including subjects older than 40 years of age and studies rated as lower quality. The lack of a robust association between IL-1β and major depression might be partly attributable to measurement issues, as the concentrations of IL-1β are very low in blood and therefore more difficult to determine accurately using conventional immunological assays. Further research on a range of IL-1-family proteins (e.g. IL1Ra, soluble ILRII or soluble ST2), in addition to IL-1β, could increase our understanding of the role of IL-1 in major depression.

In general, the strength of the association between inflammation and major depression may vary depending on methods of depression diagnosis, sample characteristics, and control for confounders. For example, the relationships between venous blood levels of IL-6, CRP and depression have been weaker in studies using self-reported instruments rather than clinical diagnosis to ascertain depression, in community-based subjects compared to clinical samples, and when participants treated with antidepressants at the time of immune assessment have been included in the analysis ([@b0135; @b0160; @b0165; @b0175]). Furthermore, it is plausible that different subtypes of depressive disorder may be associated with different inflammatory profiles ([@b0080; @b0200; @b0210]). Similarly, chronic diseases, severity of depressive symptoms and comorbid psychiatric disorders may affect the magnitude of the associations between inflammation and major depression ([@b0165; @b0175; @b0190; @b0375; @b0415]). The majority of major depressive patients included in our meta-analysis could be classified as severely or very severely depressed; IL-6, CRP and TNF-α were more strongly associated with severe than non-severe forms of depression. In an attempt to minimise the effect of chronic diseases and medications on immune-depression associations, we only included patients free of major chronic diseases and antidepressant use at the time of blood sampling in our sensitivity analysis. These analyses revealed that the association between IL-6, CRP and major depression remained strong and unaltered in studies of higher quality and antidepressant-free patients.

Compared to the most recent meta-analyses on this topic ([@b0075; @b0255]), our cumulative meta-analysis includes seven additional articles on IL-6 and eight on TNF-α that employed subjects not on antidepressants treatment and free of major physical diseases. We also included 10 additional studies on IL-6 and 13 on TNF-α allowing the use of medications and investigated those studies as a subgroup. One previous meta-analysis assessing the association between CRP, IL-6 and depression employed more relaxed inclusion criteria and sample material which may partially explain the smaller overall effect size estimates described in that study (CRP, *d* = 0.15 and IL-6, *d* = 0.25) ([@b0175]). The meta-analysis conducted by [@b0165] found that the association between IL-6 and depression did not significantly differ between smokers and non-smokers and samples analysed by different processing techniques. However, in agreement with our cumulative meta-analysis and previous standard meta-analyses, inclusion of patients using psychotropic medication and the lack of adjustment for overweight/obesity resulted in slightly larger effect size estimates between the levels of CRP, IL-6 and depression ([@b0165; @b0175]).

The observed heterogeneity between study-specific effect estimates was either high (TNF-α and IL-1β) or moderate (IL-6 and CRP). While some of the subgroup analyses, e.g. studies including older subjects or patients with moderate depression (IL-1β), younger participants (CRP) or more men (IL-6) were associated with reduced overall heterogeneity between studies, none of these factors significantly affected the overall associations. On the other hand, heterogeneity remained high (*I*^2^ \> 79%) in all additional analyses examining the relationship between TNF-α and major depression. These results indicate that some other undefined factors may be modifying the observed associations. For example, genetic variations and brain abnormalities have been proposed to be associated with depression-related immune activation ([@b0010; @b0345]) and developmental influences, such as childhood trauma, may also be linked to increased vulnerability to develop psychiatric disorders in later life via inflammatory processes ([@b0405]). Furthermore, it is possible that inflammation is only linked to some specific characteristic symptoms of major depression. Exploration of the role of gene-environment interactions and other potential moderators affecting on the strength and the nature of immune--depression relationships remains a challenge for future investigators.

The limitations of the current study need to be taken into account when interpreting the results. First, when determining the co-occurrence of inflammation and major depression, we focused on a cross-sectional association based on one-time assessments of inflammatory markers, although these measurements cannot reliably distinguish between chronic and acute inflammation. The few previous studies assessing chronic inflammation have revealed stronger associations with mental health when inflammation is determined using repeated measurements rather than only one measurement ([@b0120; @b0225]). If this also applies to the situation with major depression, then the present data may, if anything, underestimate the role of the specific inflammation markers in major depressive disorders. Due to the lack of longitudinal studies using repeated immune assessments to investigate the role of inflammation in clinically depressed patients, the strength of these associations remains uncertain.

Second, the lack of well-designed and adequately controlled studies (none of the included studies received a maximum quality score of 9% and 41% of all studies were scored as low quality, scores 0--5) highlight the need for future studies with improved study designs and more comprehensive control for confounding variables. Third, as only four studies on IL-6 and seven on TNF-α had differentiated data for different subtypes of major depression (e.g. melancholic, atypical, suicidal, recurrent and/or treatment-resistant depression) we could not include a more detailed analysis assessing the association of subtypes of major depressive disorders with circulating inflammatory markers. Fourth, comparison of major depression patients with and without comorbid conditions with healthy controls may inflate the observed group differences because a number of comorbid conditions may increase both inflammation and depression. Therefore, future studies investigating the association between inflammation and major depression should pay more attention to ensure that they control properly for the inflammatory effects of physical conditions.

5. Conclusions {#s0105}
==============

Cumulative meta-analyses are important in collating the totality of data, potentially helping researchers and funders to make informed decisions about the sufficiency of evidence and to set priorities for new studies. Ideally, this will contribute to a faster accumulation of knowledge and reduced costs and effort by preventing unnecessary research. Our cumulative meta-analysis of four inflammatory markers sought to bring together the findings from studies on the co-occurrence of elevated systemic levels of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein and major depressive disorders. The strong evidence of increased circulating concentrations of interleukin-6 and C-reactive protein in patients with major depressive disorder but not on antidepressant medication compared with non-depressed individuals confirms the cross-sectional association between inflammation and major depression. Peripherally administered IL-6 has been shown to cross the blood--brain barrier ([@b9000]), suggesting that immunomodulatory studies aimed at reducing IL-6 in subgroups of patients with an elevated inflammatory profile could have potential in the treatment of patients with depression and enhanced levels of inflammation. While concentrations of TNF-α and IL-1β appeared to be elevated in certain subgroups of patients, the role of confounding factors, such as age and obesity, should be taken into account when planning future research on these immune markers. Furthermore, future studies are needed to monitor symptomatic presentations, classify depressive symptoms and control more comprehensively for confounders potentially interfering with immune--depression relations (including lifestyle factors, other psychiatric disorders, comorbid physical conditions and medications used at the time of assessments). More attention should also be paid to the accuracy of the measurement of IL-1β.
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###### 

Summary statistics on the associations between levels of CRP, IL-6, TNF-α and IL-1β and major depressive disorder in different subgroups.

                                                              IL-6   CRP    TNF-α   IL-1β                                                                                                             
  ----------------------------------------------------------- ------ ------ ------- ------- ------ ---- ------ ------- ------ ------ ---- ------- ------- ------- ------ ---- ------- ------- ------- ------
  All studies                                                 31     0.54   0.000   68.5    56.2   20   0.46   0.000   50.9   62.3   31   0.40    0.002   253.8   88.2   14   −0.05   0.860   197.2   93.4
  Subjects not using antidepressants                          22     0.59   0.000   43.8    52.1   10   0.60   0.001   31.5   71.4   19   0.54    0.001   138.5   87.0   12   −0.09   0.758   187.7   94.1
  Subjects using medication                                   10     0.43   0.000   19.2    53.2   10   0.36   0.000   15.3   41.3   13   0.28    0.211   111.1   89.2   3    0.16    0.690   7.60    73.7
  Study subjects under 40 years old                           13     0.51   0.000   19.7    39.0   10   0.45   0.000   9.19   2.0    16   0.56    0.001   117.9   87.3   9    −0.45   0.205   139.9   94.3
  Study subjects over 40 years old                            18     0.58   0.000   48.7    65.1   10   0.52   0.003   41.9   78.5   15   0.21    0.300   132.5   89.4   5    0.65    0.000   6.65    39.9
  \>50% of study subjects female                              19     0.53   0.000   46.4    61.2   14   0.52   0.000   38.9   66.5   23   0.40    0.004   175.1   87.4   12   −0.05   0.858   186.7   94.1
  \<50% of study subjects female                              10     0.55   0.000   11.5    22.0   4    0.31   0.255   10.6   71.7   7    0.55    0.122   73.6    91.8   2    0.02    0.979   5.47    81.7
  BMI controlled                                              16     0.48   0.000   36.2    58.5   11   0.39   0.000   11.2   10.8   16   0.25    0.129   123.7   87.9   8    −0.12   0.710   97.7    92.8
  BMI not controlled                                          15     0.62   0.000   30.4    54.0   8    0.55   0.005   35.2   80.1   15   0.57    0.006   128.9   89.1   6    0.04    0.938   89.5    94.4
  Study size \< 50                                            14     0.51   0.000   24.6    47.1   9    0.36   0.042   20.4   60.8   11   0.53    0.150   121.5   91.8   4    0.33    0.271   9.07    66.9
  Study size ⩾ 50                                             17     0.56   0.000   43.8    63.5   11   0.53   0.000   29.7   66.4   20   0.32    0.007   123.0   84.5   10   −0.18   0.598   181.0   95.0
  Study subjects inpatients                                   10     0.60   0.000   24.8    63.7   7    0.53   0.012   35.7   83.2   8    0.44    0.017   33.9    79.3   3    −0.19   0.453   7.22    72.3
  Study subjects outpatients                                  18     0.45   0.000   31.4    45.8   10   0.38   0.000   10.4   13.2   19   0.24    0.190   176.4   89.8   10   −0.12   0.748   165.5   94.6
  Quality score \< 6                                          10     0.41   0.000   13.2    32.0   10   0.26   0.032   20.0   54.9   13   0.58    0.006   85.3    85.9   5    0.61    0.004   10.5    61.9
  Quality score ⩾ 6                                           21     0.60   0.000   52.6    62.0   10   0.69   0.000   21.7   58.5   18   0.28    0.089   159.3   89.3   9    −0.36   0.291   142.5   94.4
  Mild/moderate depression[a](#tblfn1){ref-type="table-fn"}   6      0.46   0.054   21.6    76.9   5    0.37   0.011   4.92   19.7   7    −0.16   0.568   58.9    89.8   3    0.64    0.000   1.25    0.00
  Severe depression[b](#tblfn2){ref-type="table-fn"}          21     0.62   0.000   37.7    47.0   13   0.50   0.000   45.4   73.6   22   0.58    0.000   177.2   88.2   11   −0.25   0.431   171.7   94.2

Mild/moderate depression: score \<19 (HAMD), \<35 (MADRS), \<39 (IDS) or \<30 (BDI).

Severe depression: score ⩾19 (HAMD), ⩾35 (MADRS), ⩾39 (IDS) or ⩾30 (BDI).
